RyanCassadayMD

PubMed

• Retrospective review of the toxicities and change in dosing patterns for pegaspargase in patients with acute lymphoblastic leukemia/lymphoma and T-cell lymphoma.
  Grace Baek, Miryoung Kim, Madison Lee, Shan O'Connor, Lauren Held, Lars van der Laan, Ryan D Cassaday> ;Journal of Oncology Pharmacy Practice. 2024 Apr 13
• Single agent subcutaneous blinatumomab for advanced acute lymphoblastic leukemia.
  Elias Jabbour, Gerhard Zugmaier, Vaibhav Agrawal, Pilar Martínez-Sánchez, José J Rifón Roca, Ryan D Cassaday, Boris Böll, Anita Rijneveld, Maher Abdul-Hay, Françoise H...> ;American Journal of Hematology. 2024 Apr 1
• 1 citations
  Timing of anti-PD-L1 antibody initiation affects efficacy/toxicity of CD19 CAR T-cell therapy for large B-cell lymphoma.
  Alexandre V Hirayama, Erik L Kimble, Jocelyn H Wright, Salvatore Fiorenza, Jordan Gauthier, Jenna M Voutsinas, Qian Wu, Cecilia C S Yeung, Nicolas Gazeau, Barbara S Pe...> ;Blood Advances. 2024 Jan 23
• 1 citations
  Craniospinal irradiation for CNS leukemia: rates of response and durability of CNS control.
  Morse, M., Gooley, T., Blau, M., Ebadi, M., Ermoian, R., Halasz, L., Lo, S., Yang, J., Percival, M., Cassaday, R., Graber, J., Taylor, L., Venur, V., Tseng, Y.> ;Journal of Neuro-Oncology. 2024 Jan 1
• Answering the "Doctor, can CAR-T therapy cause cancer?" question in clinic.
  Banerjee, R., Hirayama, A., Gauthier, J., Cassaday, R., Shadman, M., Cowan, A., Till, B., Green, D., Kiem, H., Gopal, A., Maloney, D., Banerjee, R., Poh, C.> ;Blood Advances. 2024 Feb 27
• Asparaginase dosing for obese patients with acute lymphoblastic leukemia and factors that contribute to outcomes.
  Cassaday, R.> ;Best Practice & Research. Clinical Haematology. 2023 Dec 1
• 2 citations
  Factors associated with long-term outcomes of CD19 CAR T-cell therapy for relapsed/refractory CLL.
  Emily C Liang, Aya Albittar, Jennifer J Huang, Alexandre V Hirayama, Erik L Kimble, Andrew J Portuguese, Aude Chapuis, Mazyar Shadman, Brian G Till, Ryan D Cassaday, F...> ;Blood Advances. 2023 Nov 28
• Pembrolizumab With R-CHOP in Previously Untreated DLBCL: Sustained, High Efficacy, and Safety With Long-Term Follow-Up.
  Carrie Ho, Ajay K Gopal, Brian G Till, Mazyar Shadman, Ryan C Lynch, Andrew J Cowan, Qian V Wu, Jenna Voutsinas, Heather A Rasmussen, Katherine Blue, Chaitra S Ujjani,...> ;Clinical Lymphoma, Myeloma & Leukemia. 2024 Feb 1
• Phase 1/2 study of sorafenib added to cladribine, high-dose cytarabine, G-CSF, and mitoxantrone in untreated AML.
  Anna B Halpern, Eduardo Rodríguez-Arbolí, Megan Othus, Kelsey-Leigh A Garcia, Mary-Elizabeth M Percival, Ryan D Cassaday, Vivian G Oehler, Pamela S Becker, Jacob S App...> ;Blood Advances. 2023 Sep 12
• 2 citations
  Impact of prior therapies and subsequent transplantation on outcomes in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with bre...
  Bijal D Shah, Ryan D Cassaday, Jae H Park, Roch Houot, Olalekan O Oluwole, Aaron C Logan, Nicolas Boissel, Thibaut Leguay, Michael R Bishop, Max S Topp, Dimitrios Tzac...> ;Journal for Immunotherapy of Cancer. 2023 Aug 1
• 3 citations
  Successful Treatment of Persistent Symptomatic Coronavirus Disease 19 Infection With Extended-Duration Nirmatrelvir-Ritonavir Among Outpatients With Hematologic Cancer.
  Catherine Liu, Leah H Yoke, Pooja Bhattacharyya, Ryan D Cassaday, Guang-Shing Cheng, Zahra Kassamali Escobar, Cristina Ghiuzeli, Denise J McCulloch, Steven A Pergam, P...> ;Open Forum Infectious Diseases. 2023 Jun 1
• 6 citations
  How I prevent and treat central nervous system disease in adults with acute lymphoblastic leukemia.
  Noam E Kopmar, Ryan D Cassaday> ;Blood. 2023 Mar 23
• 17 citations
  Two-year follow-up of KTE-X19 in patients with relapsed or refractory adult B-cell acute lymphoblastic leukemia in ZUMA-3 and its contextualization with SCHOLAR-3, an ...
  Bijal D Shah, Armin Ghobadi, Olalekan O Oluwole, Aaron C Logan, Nicolas Boissel, Ryan D Cassaday, Thibaut Leguay, Michael R Bishop, Max S Topp, Dimitrios Tzachanis, Kr...> ;Journal of Hematology & Oncology. 2022 Dec 10
• 2 citations
  Phase 1/2 Trial of CLAG-M with Dose-Escalated Mitoxantrone in Combination with Fractionated-Dose Gemtuzumab Ozogamicin for Newly Diagnosed Acute Myeloid Leukemia and O...
  Colin D Godwin, Eduardo Rodríguez-Arbolí, Megan Othus, Anna B Halpern, Jacob S Appelbaum, Mary-Elizabeth M Percival, Paul C Hendrie, Vivian G Oehler, Siobán B Keel, Ja...> ;Cancers. 2022 Jun 14
• Physician and patient perceptions on randomization of treatment intensity for unfit adults with acute myeloid leukemia and other high-grade myeloid neoplasm.
  Anna B Halpern, Megan Othus, Genevieve Alcorn, Zahra Ali, Kelsey-Leigh A Garcia, Mary-Elizabeth M Percival, Siobán B Keel, Ryan D Cassaday, Pamela S Becker, Elihu H Es...> ;Leukemia. 2022 May 1
• 6 citations
  Cerebrospinal fluid flow cytometry and risk of central nervous system relapse after hyperCVAD in adults with acute lymphoblastic leukemia.
  Kelsey-Leigh A Garcia, Sindhu Cherian, Philip A Stevenson, Christen H Martino, Andrei R Shustov, Pamela S Becker, Mary-Elizabeth M Percival, Vivian G Oehler, Anna B Ha...> ;Cancer. 2022 Apr 1
• 7 citations
  Asparaginase in the Treatment of Acute Lymphoblastic Leukemia in Adults: Current Evidence and Place in Therapy.
  Krishna R Juluri, Chloe Siu, Ryan D Cassaday> ;Blood and Lymphatic Cancer. 2022 Jan 1
• 3 citations
  Mega-dose 90Y-Ibritumomab tiuxetan prior to allogeneic transplantation is effective for aggressive large B-cell lymphoma.
  Victor A. Chow, Ryan D. Cassaday, Ted Gooley, Stephen D. Smith, Brenda M. Sandmaier, Damian J. Green, Johnnie J. Orozco, Sherilyn A. Tuazon, Manuela Matesan, Darrell R...> ;Blood Advances. 2021 Oct 14
• 33 citations
  Haploidentical vs. sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia.
  Matthew J Wieduwilt, Leland Metheny, Mei-Jie Zhang, Hai-Lin Wang, Noel Estrada-Merly, David I. Marks, A Samar Al-Homsi, Lori Muffly, Nelson J. Chao, David A. Rizzieri,...> ;Blood Advances. 2021 Sep 21
• 2 citations
  Antibody and cellular immunotherapies for acute lymphoblastic leukemia in adults.
  Ryan D. Cassaday, Kimble, E. L., Kimble, E. L., Erik L. Kimble> ;Leukemia & Lymphoma. 2021 Aug 17
• 25 citations
  Dose-dense brentuximab vedotin plus ifosfamide, carboplatin, and etoposide for second-line treatment of relapsed or refractory classical Hodgkin lymphoma: a single cen...
  Ryan C. Lynch, Ryan D. Cassaday, Stephen D. Smith, Jonathan R. Fromm, Andrew J. Cowan, Edus H. Warren, Mazyar Shadman, Andrei R. Shustov, Brian G. Till, Chaitra S. Ujj...> ;The Lancet. Haematology. 2021 Aug 1
• 248 citations
  KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study
  Bijal D. Shah, Armin Ghobadi, Olalekan O. Oluwole, Aaron C Logan, Nicolas Boissel, Ryan D. Cassaday, Thibaut Leguay, Michael R. Bishop, Max S. Topp, Dimitrios Tzachani...> ;Lancet. 2021 Aug 7
• 80 citations
  KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results.
  Bijal D. Shah, Michael R. Bishop, Olalekan O. Oluwole, Aaron C Logan, Maria R. Baer, William B. Donnellan, Kristen M. O'Dwyer, Houston Holmes, Martha Arellano, Armin G...> ;Blood. 2021 Jul 8
• 13 citations
  Inotuzumab Ozogamicin for Relapsed/Refractory Acute Lymphoblastic Leukemia in the INO-VATE Trial: CD22 Pharmacodynamics, Efficacy, and Safety by Baseline CD22.
  Hagop M. Kantarjian, Wendy Stock, Ryan D. Cassaday, Daniel J. DeAngelo, Elias Jabbour, Susan O'Brien, Matthias Stelljes, Tao Wang, M. Luisa Paccagnella, Kevin Nguyen, ...> ;Clinical Cancer Research. 2021 Feb 18
• 91 citations
  Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignancies
  Jordan Gauthier, Evandro D. Bezerra, Alexandre V. Hirayama, Salvatore Fiorenza, Alyssa Sheih, Cassie K. Chou, Erik Kimble, Barbara S. Pender, Reed M. Hawkins, Aesha Va...> ;Blood. 2021 Jan 21
• Join now to see all

Journal Articles

• Phase 1/2 Trial of Cladribine, High-Dose Cytarabine, Mitoxantrone, and G-CSF with Dose-Escalated Mitoxantrone for relapsed/refractory Acute Myeloid Leukemia or Other H...  
  Kelda M Gardner, Vivian G Oehler, Heather A Smith, Anna B Halpern, Paul C Hendrie, Sarah A Buckley, Roland B Walter, Pamela S Becker, Ryan D Cassaday, Asma Anwar, Bart..., Haematologica

Abstracts/Posters

• Comparison of Outcomes after Early Hospital Discharge (EHD) Following Intensive Induction Vs. Post-Remission Chemotherapy for Adults with Acute Myeloid Leukemia (AML) ...
  Ryan D. Cassaday, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Impact of Lab Abnormalities at the Time of Progression in Patients Receiving CD19-Specific CAR T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphomas
  Ryan D. Cassaday, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• A Phase II, Multicenter Study of High Dose Chemotherapy with Autologous Stem Cell Transplant Followed By Maintenance Therapy with Romidepsin for T-Cell Lymphoma
  Ryan D. Cassaday, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Efficacy and Safety Outcomes in the Phase 3 INO-Vate Trial By Baseline CD22 Positivity Assessed By Local Laboratories
  Ryan D. Cassaday, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Low Achievement of End of Life Quality Measures in Large B-Cell Lymphoma Patients Who Progressed after CD19-Specific CAR-T Cell Therapy
  Ryan D. Cassaday, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Ibrutinib in Relapsed or Refractory Transformed Indolent B-Cell Non-Hodgkin Lymphoma: Final Results from a Prospective Phase II Study
  Ryan D. Cassaday, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Comparison of Outcomes after Early Hospital Discharge (EHD) Following Intensive Induction Vs. Post-Remission Chemotherapy for Adults with Acute Myeloid Leukemia (AML) ...
  Ryan D. Cassaday, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Factors Associated with Response, CAR-T Cell In Vivo Expansion, and Progression-Free Survival after Repeat Infusions of CD19 CAR-T CellsClinically Relevant Abstract
  Ryan D. Cassaday, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• A Multi-Omic Precision Medicine Clinical Trial in Acute Leukemia
  Ryan D. Cassaday, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Join now to see all

Lectures

• Pembrolizumab in Combination with Standard RCHOP Therapy for Previously Untreated Diffuse Large B-Cell Lymphoma 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Factors Impacting Progression-Free Survival after CD19-Specific CAR-T Cell Therapy for Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Immunotherapy with T-Cells Engineered with a Chimeric Antigen Receptor Bearing a Human CD19-Binding Single Chain Variable Fragment for Relapsed or Refractory Acute Lym... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Efficacy and Toxicity of JCAR014 in Combination with Durvalumab for the Treatment of Patients with Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Outcomes of Patients with Large B-Cell Lymphomas and Progressive Disease Following CD19-Specific CAR T-Cell TherapyClinically Relevant Abstract 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Dose-Adjusted Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) Is Active and Well-Tolerated in Adults with Newly-Diagnosed Acute Lympho... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Extensive safety profile of inotuzumab ozogamicin (InO) in relapsed/refractory acute lymphoblastic leukemia (ALL) patients enrolled in the phase 3 INO-VATE trial. 
  2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
• Join now to see all